Hodgkin lymphoma
Haematology · 2015–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin First-line treatment of advanced (stage III or IV) CD30-positive Hodgkin lymphoma in adult patients with previously untreated disease, in combination with… | Jul 2025 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia · Lymphoma Group |
| brentuximab vedotin Relapsed or refractory Hodgkin lymphoma following at least two prior therapies when autologous stem cell transplant (ASCT) or multi-agent chemotherapy is not a… | Nov 2016 | Recommended with restriction | 4 individuals Leukaemia Foundation · Lymphoma Australia · Rare Cancer Australia |
| brentuximab vedotin Treatment of patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT). | Nov 2016 | Recommended with restriction | 8 individuals Lymphoma Australia · Leukaemia Foundation · Rare Cancer Australia |
| brentuximab vedotin Treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma following autologous stem cell transplant (ASCT). | Mar 2015 | Not recommended | 13 individuals |
Who spoke
Leukaemia Foundation · Lymphoma Australia · Rare Cancer Australia · Rare Cancers Australia · Lymphoma Group
What the PBS pays
$21M in government benefit over 2024–25, across 1,496 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| brentuximab vedotin | $21.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 3 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| brentuximab vedotinBrentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | recommended restricted | 2025-05 |
| pembrolizumabPembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | not recommended | 2018-09 |
| brentuximab vedotinBrentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | recommended restricted | 2018-06 |
| nivolumabNivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | recommended | 2017-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.